Lee, D. K., Park, S. R., Kim, Y. H., Lee, Y., Shin, S., Ahn, B., . . . Hong, M. H. A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12). Taylor & Francis Group.
Chicago Style (17th ed.) CitationLee, Dong Ki, et al. A Phase 2 Study of Spartalizumab (PDR001) Among Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (KCSG HN18-17, K-MASTER Project 12). Taylor & Francis Group.
MLA (9th ed.) CitationLee, Dong Ki, et al. A Phase 2 Study of Spartalizumab (PDR001) Among Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (KCSG HN18-17, K-MASTER Project 12). Taylor & Francis Group.
Warning: These citations may not always be 100% accurate.